Phase 2 N=172 PI-88 in Hepatocellular Carcinoma After Hepatectomy
Carcinoma, Hepatocellular
Primary: Tumour Non-recurrence Rate — 32; 40; 35 Participants — p=0.072
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=1,044 Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy
Hepatic Carcinoma
Primary: Incidence of Recurrence and Metastasis After Hepatectomy — 428; 155; 258; 161 Participants — p=0.0001
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
N/A N=76 Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI
Hepatocellular Carcinoma
Primary: Participants Without Recurrence (Disease-free). — 16; 28 Participants
Phase 3 N=70 De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
Liver Carcinoma
Primary: Percentage of Participants Surviving at One and Four Years After Liver Transplant — 85; 77 percentage of participants
N/A N=84 Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
Hepatocellular Carcinoma · HCC
Primary: SubStudy 1: Apparent Diffusion Coefficient (ADC) — 1.43 1x10^-3 mm^2/s
Phase 2 N=41 Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Liver Cancer
Primary: Response Rate by Recist Criteria — 6 participants
Phase 2 N=21 Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Participants Who Remained Free of Progression at the 27th Week. — 21 participants — p=0.0006
Phase 2 N=12 [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET — 0 Participants
Phase 1 N=10 Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
Hepatocellular Carcinoma
Primary: Number of Adverse Events — 12; 2; 8; 4 events
Phase 2 N=27 Sorafenib and TRC105 in Hepatocellular Cancer
Hepatoma · Liver Neoplasms · Adenoma, Liver Cell
Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg
Phase 2 N=60 Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Hepatocellular Carcinoma
Primary: Progression-Free Survival(PFS) — 5.7; 2.7 months — p=<0.001
Phase 3 N=458 Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Carcinoma, Hepatocellular
Primary: Time to Progression (TTP) — 164; 112 days
Phase 2 N=60 Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib
Hepatocellular Carcinoma
Primary: Overall Response Rate — 6; 30; 17; 0 Participants
Phase 2 N=11 TRC105 for Liver Cancer That Has Not Responded to Sorafenib
Hepatocellular Carcinoma · Hepatocellular Cancer · Carcinoma, Hepatocellular
Primary: Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC). — 12 Weeks
Phase 2 N=23 Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Melanoma
Primary: Ganglioside Expressed by Tumor Cells (GD2) — 3; 3; 3; 3 Participants
N/A N=105 Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration
Hepatocellular Carcinoma
Primary: Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study. — 21; 29; 14; 9 participants — p=< 0.005
Phase 2 N=26 Study of Pembrolizumab Following TACE in Primary Liver Carcinoma
Primary Liver Carcinoma
Primary: Incidence of Treatment-emergent Adverse Events (Safety and Tolerability) — 15 Participants
N/A N=77 Dose Escalation Study for Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants
Phase 2 N=20 Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants
N/A N=145 The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)
Carcinoma, Hepatocellular · Chronic Hepatitis B
Primary: 1,3,5 Year-Disease Free Survival (or Recurrence Free Survival) — 11; 13; 25; 34 participants
Phase 3 N=383 Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
Hepatocellular Carcinoma
Primary: Median Overall Survival (OS) Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular…
Phase 2 N=23 A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Advanced Hepatocellular Carcinoma · HCC · Liver Cancer
Primary: Time to Disease Progression — 8 months
Phase 3 N=959 Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Hepatocellular Carcinoma
Primary: Recurrence-Free Survival (RFS) — 46.7; 45.5 Months — p=0.7190
Phase 2 N=24 Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
Primary: Time to Progression (TTP) — 3.5 months
Phase 3 N=616 Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC
Hepatic Neoplasm Malignant Recurrent
Primary: Recurrence-free Survival — 809.0; 751.0 Days — p=0.351
Phase 2 N=3 Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
Liver Cancer · Liver Neoplasm · Hepatocellular Carcinoma
Primary: Number of Participants for Which Uptake of [18F]-FMISO Was Successful and Hypoxic Tumors Were Observed During PET Scan Imaging Post TACE Procedure — 0 Participants
Phase 2 N=30 A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment — 0.7273; 0.6429 Proportion of evaluable participants
Phase 2 N=121 Lerapolturev in Recurrent Malignant Glioma
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants
Phase 2 N=64 PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
Adult Hepatocellular Carcinoma · Localized Resectable Adult Liver Carcinoma
Primary: Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Area Under the Receiver Operating Characteristic Curve…